AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Autolus Therapeutics plc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.59−0.01 (-0.63%)
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
Autolus Therapeutics plc revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| License revenue | – | – | $1.07M | $79.00K | $29.00K | $29.00K | $10.12M | $10.09M | $10.50M | $10.50M | $1.70M | $5.52M | – | – |
| Grant | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
| Product revenue, net | – | – | $74.32M | $51.05M | $29.91M | $8.98M | $0 | – | – | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Autolus Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.